Candida Endophthalmitis: Focus on Current and Future Antifungal Treatment Options

Candida endophthalmitis is a sight‐threatening manifestation of disseminated candidiasis. The occurrence of endogenous candida endophthalmitis in patients with candidemia has ranged from 0–45% in the published literature. In critically ill patients, it has even been associated with increased mortality. In recent years, use of newer antifungal therapies for invasive candidiasis has increased given the rise in infections with non‐albicans species of Candida. To identify current practices of the management of endogenous candida endophthalmitis and relevant antifungal drug research in this disease state, we conducted a MEDLINE search (1967–2006) and bibliographic search of the English‐language literature. Treatments for candida endophthalmitis have not been evaluated through well‐designed, well‐powered clinical trials. Data have mainly been presented in case reports, case series, animal studies, pharmacokinetic studies, and as small subsets of larger trials. Traditional systemic therapies have been amphotericin B with or without flucytosine or fluconazole. Cure rates with antifungal drugs alone appear to be much higher in patients with chorioretinitis than in endophthalmitis with vitreal involvement. Pars plana vitrectomy with or without intravitreal amphotericin B injections has been advocated particularly for patients with moderate‐to‐severe vitritis and substantial vision loss. Information on new antifungal agents for endophthalmitis is limited, despite increasing use in patients with candidemia. Voriconazole may be a particularly attractive agent to consider for infections with fluconazole‐resistant, voriconazole‐susceptible strains. The current patchwork of animal studies and small patient reports provide clinicians with some insight into the role of newer agents in the treatment of candida endophthalmitis. In general, it appears that chorioretinitis infections can be more readily cured with most systemic antifungal agents, whereas more aggressive treatment, often including vitrectomy with or without intravitreal antifungal administration, is needed for patients with endophthalmitis with vitritis.

[1]  M. Choti,et al.  Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy , 2006, Journal of Clinical Microbiology.

[2]  S. Filler,et al.  Current treatment strategies for disseminated candidiasis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  H. Takebayashi,et al.  Relation between stage of endogenous fungal endophthalmitis and prognosis , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.

[4]  E. Thiel,et al.  Improved outcome in central nervous system aspergillosis, using voriconazole treatment. , 2005, Blood.

[5]  D. Andes,et al.  Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Vazquez,et al.  Anidulafungin: a new echinocandin with a novel profile. , 2005, Clinical therapeutics.

[7]  P. Moss,et al.  Use of voriconazole in candida retinitis , 2005, Eye.

[8]  J. Bradley,et al.  Candida Glabrata Endophthalmitis Treated Successfully with Caspofungin , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  W. Mieler,et al.  Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. , 2005, American journal of ophthalmology.

[10]  J. Giaconi,et al.  In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. , 2004, American journal of ophthalmology.

[11]  Lee H. Harrison,et al.  Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.

[12]  H. Flynn,et al.  Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. , 2004, American journal of ophthalmology.

[13]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Judy E. Kim,et al.  Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. , 2004, Archives of ophthalmology.

[15]  H. Flynn,et al.  Current Management of Endophthalmitis , 2004, International ophthalmology clinics.

[16]  J. Cleary,et al.  Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States , 2003, Antimicrobial Agents and Chemotherapy.

[17]  N. Wiederhold,et al.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy , 2003, Expert opinion on investigational drugs.

[18]  John W. Miller,et al.  Retinal Lesions as Clues to Disseminated Bacterial and Candidal Infections: Frequency, Natural History, and Etiology , 2003, Medicine.

[19]  P. Kaiser,et al.  Endogenous Endophthalmitis: An 18-Year Review of Culture-Positive Cases at a Tertiary Care Center , 2003, Medicine.

[20]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[21]  K. Rohrer,et al.  Ocular Distribution of Intravenously Administered Lipid Formulations of Amphotericin B in a Rabbit Model , 2002, Antimicrobial Agents and Chemotherapy.

[22]  B. Potoski,et al.  The safety of voriconazole. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Walsh,et al.  Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits , 2002, Antimicrobial Agents and Chemotherapy.

[24]  M. Pfaller,et al.  In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp , 2002, Antimicrobial Agents and Chemotherapy.

[25]  S. Piscitelli,et al.  Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits , 2001, Antimicrobial Agents and Chemotherapy.

[26]  R. Wyse,et al.  Pharmacotherapy of fungal eye infections , 2001, Expert opinion on pharmacotherapy.

[27]  S. Piscitelli,et al.  Pharmacokinetic and Pharmacodynamic Modeling of Anidulafungin (LY303366): Reappraisal of Its Efficacy in Neutropenic Animal Models of Opportunistic Mycoses Using Optimal Plasma Sampling , 2001, Antimicrobial Agents and Chemotherapy.

[28]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[29]  M. Klepser,et al.  Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.

[30]  D. Wilks,et al.  Successful treatment of Candida glabrata endophthalmitis with amphotericin B lipid complex (ABLC). , 2000, The Journal of infection.

[31]  C. Lowder,et al.  Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? , 2000, Eye.

[32]  V. Yu,et al.  Antimicrobial Therapy and Vaccines , 1999 .

[33]  J. Kylstra,et al.  Worsening of endogenous Candida albicans endophthalmitis during therapy with intravenous lipid complex amphotericin B. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  D. Slain Lipid‐Based Amphotericin B for the Treatment of Fungal Infections , 1999, Pharmacotherapy.

[35]  J. Bradley,et al.  Obturator internus muscle abscess in children: report of seven cases and review. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Carpenter,et al.  Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Michael H. Miller,et al.  Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. , 1998, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[38]  C. Y. Yu,et al.  Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. , 1998, The Journal of antimicrobial chemotherapy.

[39]  W. Smiddy Treatment outcomes of endogenous fungal endophthalmitis. , 1998, Current opinion in ophthalmology.

[40]  H. Flynn,et al.  Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. , 1997, Ophthalmic surgery and lasers.

[41]  O. Lortholary,et al.  Intravenous penetration of fluconazole during endophthalmitis. , 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[42]  W. Smiddy,et al.  Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. , 1996, Ophthalmic surgery and lasers.

[43]  S. Lightman,et al.  Candida endophthalmitis. , 1995, The British journal of ophthalmology.

[44]  B. Kubak,et al.  Treatment of ocular fungal infections with oral fluconazole. , 1995, American journal of ophthalmology.

[45]  S. Walmsley,et al.  Use of fluconazole in the treatment of candidal endophthalmitis. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  M. Levenstein,et al.  A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .

[47]  R. Devenyi,et al.  Mortality of hospitalized patients with Candida endophthalmitis. , 1994, Archives of internal medicine.

[48]  A. Eller,et al.  Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. , 1994, Ophthalmology.

[49]  S. F. Urbak,et al.  Fluconazole in the management of fungal ocular infections. , 1994, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[50]  J. Ruskin,et al.  Failure of therapy with fluconazole for candidal endophthalmitis. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  A. R. Noriega,et al.  Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts , 1993, Mycoses.

[52]  J. Miro,et al.  Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  A. Chignell Endogenous Candida Endophthalmitis , 1992, Journal of the Royal Society of Medicine.

[54]  R. Guthoff,et al.  Endogene Candida-Endophthalmitis bei einem Drogenabhängigen : intravenöse Therapie mit liposomal verkapseltem Amphotericin B , 1992 .

[55]  D. McQuillen,et al.  Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  J. B. Dickey,et al.  Endogenous Candida endophthalmitis after intravenous anesthesia with propofol. , 1991, Archives of ophthalmology.

[57]  S. Filler,et al.  Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits , 1991, Antimicrobial Agents and Chemotherapy.

[58]  W. S. Head,et al.  Ocular uptake of fluconazole following oral administration. , 1990, Archives of ophthalmology.

[59]  B. Strom,et al.  Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. , 1989, The American journal of medicine.

[60]  R. Brooks,et al.  Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. , 1989, Archives of internal medicine.

[61]  S. Pflugfelder,et al.  Complications of intraocular antimicrobial agents. , 1989, International ophthalmology clinics.

[62]  R F Woolson,et al.  Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.

[63]  J. Perfect,et al.  Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis , 1987, Antimicrobial Agents and Chemotherapy.

[64]  W. S. Head,et al.  Intraocular penetration of systemically administered antifungal agents. , 1985, Current eye research.

[65]  G. Chader,et al.  PHARMACOLOGY OF THE EYE , 1984, Handbook of Experimental Pharmacology.

[66]  A. Espinel-Ingroff,et al.  Penetration of amphotericin B into the human eye. , 1983, The Journal of infectious diseases.

[67]  D. Henderson,et al.  Hematogenous candida endophthalmitis in patients receiving parenteral hyperalimentation fluids. , 1981, The Journal of infectious diseases.

[68]  L. M. Aiello,et al.  Closed vitreous surgery. XVII. Results and complications of pars plana vitrectomy. , 1980, Archives of ophthalmology.

[69]  A. Friedman,et al.  Ocular penetration of 5-fluorocytosine. , 1978, Investigative ophthalmology & visual science.

[70]  R. Luke ENTEROTOXIN‐PRODUCING Escherichia coli AND DIARRHOEA AMONG NEWBORN BABIES IN DARWIN , 1978, The Medical journal of Australia.

[71]  J. O. Morrison,et al.  Experimental hematogenous endophthalmitis due to Candida: species variation in ocular pathogenicity. , 1977, The Journal of infectious diseases.

[72]  B. Jones,et al.  Principles in the management of oculomycosis. XXXI Edward Jackson memorial lecture. , 1975, American journal of ophthalmology.

[73]  W. Green,et al.  Intravitreal amphotericin B toxicity. , 1974, American journal of ophthalmology.

[74]  J. Edwards,et al.  OCULAR MANIFESTATIONS OF CANDIDA SEPTICEMIA: REVIEW OF SEVENTY-SIX CASES OF HEMATOGENOUS CANDIDA ENDOPHTHALMITIS , 1974, Medicine.

[75]  D. Robertson,et al.  Endogenous Candida oculomycosis. Report of two patients treated with flucytosine. , 1974, Archives of ophthalmology.

[76]  J. R. Griffin,et al.  Blood-borne Candida endophthalmitis. A clinical and pathologic study of 21 cases. , 1973, Archives of ophthalmology.

[77]  E. Schubert [Fungal infections of the eye]. , 1970, Klinische Monatsblatter fur Augenheilkunde.

[78]  A. B. Richards,et al.  Corneal and intra-ocular infection by Candida albicans treated with 5-fluorocytosine. , 1970, Transactions of the ophthalmological societies of the United Kingdom.

[79]  W. Green,et al.  OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS. , 1965, Archives of ophthalmology.